MAIVeSS : streamlined selection of antigenically matched, high-yield viruses for seasonal influenza vaccine production
© 2024. The Author(s)..
Vaccines are the main pharmaceutical intervention used against the global public health threat posed by influenza viruses. Timely selection of optimal seed viruses with matched antigenicity between vaccine antigen and circulating viruses and with high yield underscore vaccine efficacy and supply, respectively. Current methods for selecting influenza seed vaccines are labor intensive and time-consuming. Here, we report the Machine-learning Assisted Influenza VaccinE Strain Selection framework, MAIVeSS, that enables streamlined selection of naturally circulating, antigenically matched, and high-yield influenza vaccine strains directly from clinical samples by using molecular signatures of antigenicity and yield to support optimal candidate vaccine virus selection. We apply our framework on publicly available sequences to select A(H1N1)pdm09 vaccine candidates and experimentally confirm that these candidates have optimal antigenicity and growth in cells and eggs. Our framework can potentially reduce the optimal vaccine candidate selection time from months to days and thus facilitate timely supply of seasonal vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 06. Feb., Seite 1128 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gao, Cheng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.02.2024 Date Revised 11.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-45145-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368102289 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368102289 | ||
| 003 | DE-627 | ||
| 005 | 20240211232016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-45145-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM368102289 | ||
| 035 | |a (NLM)38321021 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gao, Cheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MAIVeSS |b streamlined selection of antigenically matched, high-yield viruses for seasonal influenza vaccine production |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.02.2024 | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Vaccines are the main pharmaceutical intervention used against the global public health threat posed by influenza viruses. Timely selection of optimal seed viruses with matched antigenicity between vaccine antigen and circulating viruses and with high yield underscore vaccine efficacy and supply, respectively. Current methods for selecting influenza seed vaccines are labor intensive and time-consuming. Here, we report the Machine-learning Assisted Influenza VaccinE Strain Selection framework, MAIVeSS, that enables streamlined selection of naturally circulating, antigenically matched, and high-yield influenza vaccine strains directly from clinical samples by using molecular signatures of antigenicity and yield to support optimal candidate vaccine virus selection. We apply our framework on publicly available sequences to select A(H1N1)pdm09 vaccine candidates and experimentally confirm that these candidates have optimal antigenicity and growth in cells and eggs. Our framework can potentially reduce the optimal vaccine candidate selection time from months to days and thus facilitate timely supply of seasonal vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 700 | 1 | |a Wen, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Minhui |e verfasserin |4 aut | |
| 700 | 1 | |a Hatuwal, Bijaya |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Praena, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Cynthia Y |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jieze |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Webby, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Yizhi Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Xiu-Feng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 06. Feb., Seite 1128 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:06 |g month:02 |g pages:1128 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-45145-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 06 |c 02 |h 1128 | ||